Navigation Links
S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award
Date:3/5/2009

SINGAPORE, March 6 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. Dr. Stephen Rhind, Senior Vice President Corporate Development, S*BIO, received the award on behalf of the company, from Mr. S. Iswaran, Singapore's Senior Minister for Trade and Industry.

The Annual BioSpectrum awards recognize outstanding contributions to the growth of the biotechnology and life sciences industry in Asia. S*BIO was chosen for its innovative business model and leading position in Singapore's biotechnology industry.

"We are proud to be named Singapore's emerging bioscience company of the year," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Receiving this award not only reflects S*BIO's leading role in oncology drug discovery and development but also demonstrates the commitment of Singapore's government to the local biomedical sciences industry.

"We thank everyone at S*BIO whose combined efforts led to the significant progress we made in moving our leading candidates, the JAK2 inhibitors SB1518 and SB1578, the HDAC inhibitor SB939, and the multi-kinase inhibitor SB1317, through pre-clinical and clinical development."

About BioSpectrum

Launched in 2003 by Asia's leading specialty publishing company, CyberMedia India Ltd., BioSpectrum is India's and Asia-Pacific's most widely circulated and read Life Sciences media platform. It comes out in two monthly editions: India edition published from Banglaore and an Asian edition, printed and published from Singapore. The business-to-business magazine tracks the growth of life science companies, captures the emerging technological and entrepreneurial trends in the area of Life Sciences which include pharmaceutical, biotechnology, medical technology, bio-agriculture and bio-fuels. The combined readership of both the editions of the magazine, which is available in multiple formats as a fortnightly digital magazine, Web site, with updated daily news and daily electronic newsletter, is over 200,000. The readership includes the region's top policy makers, scientists, entrepreneurs, industry leaders, other influencers who are part of the Life Sciences ecosystem. The Web sites of the two editions have over 100,000 unique visitors.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, also entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multi-kinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. More information about S*BIO can be found at www.sbio.com.

    S*BIO Pte Ltd:                    Russo Partners:
    Stephen Keith Rhind, Ph.D.        Tony Russo +1 212-845-4251
    Senior Vice President,            Tony.Russo@russopartnersllc.com
     Corporate Development
    Tel: +65 6827 5000 (Singapore)    Andreas Marathovouniotis +1 212-845-4235
    Stephen_rhind@sbio.com            Andreas.Marathis@russopartnersllc.com


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
2. S*BIO Completes US$26 Million Equity Financing
3. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
4. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
5. AMPAC Fine Chemicals Receives the California Pollution Prevention Challenge Award Two Consecutive Years
6. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
7. Advanced Life Sciences Receives Notice of Planned Cethromycin Review by FDA Advisory Committee
8. Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair
9. Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
10. IlluminOss Medical Receives ISO 13485 Certification
11. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):